## MOH: Molina Healthcare, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.4% in lower entry zone (4.0-10.0%), top quartile (81st pct) cross-sectional ranking. Caution: MRS_5 (-0.7%) diverging from MRS_20, watch for reversal. Outperforming sector by 4.5%. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($152.25)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 7
- **Sentiment:** Bearish (Bullish: 0, Bearish: 5)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Investors to Learn More About the Investigation**
- Source: KSNT 27 News | 20251222T040803 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Molina securities before February 5, 2025, and still hold them, to assist with the investigation. This investigation focuses on potential claims against Molina and its officers/directors.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Investors to Learn More About the Investigation**
- Source: FOX40 News | 20251221T160907 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) concerning potential corporate wrongdoing by the company and its officers/directors. Investors who purchased Molina securities prior to February 5, 2025, and still hold them, are urged to contact the firm for more information and to assist in the investigation. The firm operates on a contingency fee basis, meaning there is no cost to investors unless a successful recovery is made.

**3. Assenagon Asset Management S.A. Purchases 72,366 Shares of Molina Healthcare, Inc $MOH**
- Source: MarketBeat | 20251220T080808 | Somewhat-Bearish | Relevance: 100%
- Assenagon Asset Management S.A. significantly increased its stake in Molina Healthcare, Inc. by 1,015.4% in the third quarter, acquiring 72,366 additional shares to reach a total of 79,493 shares valued at approximately $15.21 million. Despite this institutional interest, Molina Healthcare missed Q3 EPS expectations and faces a "Hold" consensus rating from analysts with an average price target of $196.33. Insiders also saw a director sell 357 shares, reducing his position by 3.05%.

**4. Attention Long-Term Shareholders of Cytokinetics, Inc.**
- Source: GlobeNewswire | 20251222T140831 | Bearish | Relevance: 100%
- Grabar Law Office is investigating claims on behalf of long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Holley Inc. (NYSE: HLLY), Molina Healthcare, Inc. (NYSE: MOH), and WEBTOON Entertainment, Inc. (NASDAQ: WBTN). The investigations concern alleged breaches of fiduciary duties by company officers and directors, stemming from issues like misleading statements, delayed disclosures, and the survival of securities fraud class action complaints. Shareholders with holdings prior to specified dates are encouraged to contact the law office to potentially seek corporate reforms and other remedies.

**5. The MolinaCares Accord and Molina Healthcare of Nevada Donate $187,000 to Support Local Food Banks Facing Increased Demand**
- Source: Business Wire | 20251222T150312 | Somewhat-Bullish | Relevance: 92%
- The MolinaCares Accord and Molina Healthcare of Nevada have donated $187,000 to Three Square Food Bank and Food Bank of Northern Nevada to combat rising food insecurity in the state. This donation comes as both organizations report a significant increase in demand, partly due to the temporary government shutdown impacting SNAP benefits. The grants will help fund emergency response efforts and provide approximately 150,000 meals, building on Molina's broader commitment to improving Nevadans' health and well-being.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Elevated short interest (11.4%): bears positioning against stock.
2. Long-term trend broken: trading 28.6% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.53 signals overvaluation risk, limited margin of safety. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.9B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.53 |
| Forward P/E | 10.8 |
| Current P/E | 11.8 |
| YoY Growth | 9.4% |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 6.6% to 4.4% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 81st percentile. MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.0% shows strong absolute momentum above own 20MA. Outperforming sector by 4.5pp, stock-specific strength. Below SMA200 (0.71x), long-term trend not supportive. MACD histogram positive (1.44), confirming momentum. RSI neutral at 59. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.40% (CS: 81) | Strong |
| RSI_14 | 59.3 | Neutral |
| MACD Histogram | 1.44 | Bullish |
| vs SMA20 | 1.050x | Above |
| vs SMA50 | 1.033x | Above |
| vs SMA200 | 0.714x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $163.79
- **Stop Loss:** $152.25 (7.0% risk)
- **Target:** $181.10 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 103
- **Position Value:** $16,870.37
- **Portfolio %:** 16.87%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*